NCT00956410View on ClinicalTrials.gov

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

CAD106

Trial Locations (4)

Unknown

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Stockholm

Novartis Investigative Site, Basel

Novartis Investigative Site, Southampton

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY